NBP (NovaBridge Biosciences) EV-to-FCF: (As of Jun. 27, 2026)


NBP NovaBridge Biosciences NBP
32 GF Score
Price $1.65
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NovaBridge Biosciences's Enterprise Value is $-17.53 Mil. NovaBridge Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. Therefore, NovaBridge Biosciences's EV-to-FCF for today is .

The historical rank and industry rank for NovaBridge Biosciences's EV-to-FCF or its related term are showing as below:

NBP' s EV-to-FCF Range Over the Past 10 Years
Min: -26.3   Med: -2.55   Max: 62.84
Current: 0.85

During the past 9 years, the highest EV-to-FCF of NovaBridge Biosciences was 62.84. The lowest was -26.30. And the median was -2.55.

NBP's EV-to-FCF is ranked better than
77.18% of 333 companies
in the Biotechnology industry
Industry Median: 14.65 vs NBP: 0.85

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-27), NovaBridge Biosciences's stock price is $1.645. NovaBridge Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.483. Therefore, NovaBridge Biosciences's PE Ratio (TTM) for today is At Loss.


NovaBridge Biosciences  (NAS:NBP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

NovaBridge Biosciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.645/-0.483
=At Loss

NovaBridge Biosciences's share price for today is $1.645.
NovaBridge Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.483.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


NovaBridge Biosciences EV-to-FCF Related Terms


NovaBridge Biosciences EV-to-FCF Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences EV-to-FCF Chart

NovaBridge Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -19.92 2.75 2.12 1.90 -12.20

NovaBridge Biosciences Quarterly Data
Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 0.00 0.00 0.00 -12.20

NBP vs ELTX, CNTN, INDP: EV-to-FCF Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBridge Biosciences EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's EV-to-FCF falls into.


NBP
32GF Score
NovaBridge Biosciences NBP
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovaBridge Biosciences EV-to-FCF Calculation

NovaBridge Biosciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-17.533/0
=

NovaBridge Biosciences's current Enterprise Value is $-17.53 Mil.
NovaBridge Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovaBridge Biosciences Business Description

Other Exchanges 0VY:Germany
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
32GF Score

Get the complete analysis for NBP

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price